- This event has passed.
Presenting: Parman Tech, Inc. – Precision Nanoparticle Solutions
March 19 @ 9:00 AM - 10:30 AM
Parman Tech, Inc. (http://www.parmantech.com) – Co-Founder John J. Curry presenting, is advancing pharmaceutical innovation with laser-powered technology for precise characterization and purification of therapeutic nanoparticles.
Targeted drug delivery using nanoparticles is transforming the pharmaceutical treatment of cancer and other critical diseases, with over 50 approved drugs and more than 500 in clinical trials. However, the current methods for manufacturing and characterizing these nanoparticles remain inefficient and lack the precision needed for the next level of quality and regulatory compliance.
Parman Tech’s revolutionary laser-based technology addresses this gap by using optical forces to achieve unparalleled precision in nanoparticle purification and characterization, setting a new industry standard.
Our target market is pharmaceutical companies and research institutions in the US that need precise, scalable nanoparticle manufacturing solutions and are willing to invest in cutting-edge technology to meet regulatory demands and improve therapeutic outcomes.
Our competition includes traditional filtration systems, centrifugation methods, and chromatography-based purification techniques. Parman Tech’s competitive advantage lies in its unique laser-based approach that offers superior accuracy, scalability, and compliance with regulatory standards, reducing manufacturing costs and accelerating time-to-market for life-saving therapies.
The total nanoparticle drug delivery market size in 2024 is $75B, projected to grow to $120B by 2030.
Top 3 Challenges:
- Securing funding to scale technology development.
- Adding a life scientist with expertise in therapeutic nanoparticle production to the team.
- Building strategic partnerships with pharmaceutical companies and research institutions.
Our Pitch Boulder Ask: We’re seeking feedback on how to best position Parman Tech for its first significant outside investment, introductions to potential customers and strategic partners, and recommendations for experienced life scientists to join our mission of revolutionizing nanoparticle-based drug delivery.